OX40 Monoclonal Antibody (OX86), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | MA170087-Each-of-1 | In Stock | ₹ 44,188.50 |
MA170087 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 44,188.50
GST (18%): ₹ 7,953.93
Total Price: ₹ 52,142.43
Antigen
OX40
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
P47741
Gene Symbols
Tnfrsf4
Immunogen
Recombinant mouse OX-40 antigen.
Quantity
250 μg
Primary or Secondary
Primary
Target Species
Mouse
Product Type
Antibody
Isotype
IgG1
Applications
Flow Cytometry
Clone
OX86
Conjugate
Unconjugated
Gene
Tnfrsf4
Gene Alias
ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l
Host Species
Rat
Purification Method
Protein G
Regulatory Status
RUO
Gene ID (Entrez)
22163
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- MA1-70087 detects CD134 in mouse samples
- MA1-70087 has been successfully used in flow cytometry procedures
- The MA1-70087 immunogen is recombinant mouse OX-40 antigen
- OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system
- When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents
- OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer
- They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.